Deciphera, a member of ONO, is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.
Enabled by our proprietary drug discovery platform, Deciphera has developed a diverse pipeline of wholly-owned drug candidates. QINLOCK® (ripretinib) is Deciphera’s switch control inhibitor developed for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United States, and the United Kingdom. We wholly own QINLOCK and all of our drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China. In addition to QINLOCK, we have identified and advanced multiple product candidates from our platform into clinical studies, including vimseltinib and DCC-3116.
See here for more details on our portfolio.
We offer an outstanding culture and opportunity for personal and professional growth guided by our “PATHS” Core Values and how we work together. We are proud to be Great Place to Work Certified 2023 and rank #25 on Fortune’s Best Places to Work Small and Midsized Biotech Companies in 2023. Find more details about our award-winning culture here.
Deciphera is seeking a seasoned, dynamic commercial leader with extensive product launch experience to lead the company’s commercial training, engagement and brand communications capabilities. The Director will be responsible for CTCE strategy and execution for the company’s broad and diverse oncology portfolio including its lead asset QINLOCK, a highly-selective, broad-spectrum KIT and PDGFRa kinase switch control inhibitor currently on the market for the treatment of GIST, and prepare for the launch of vimseltinib, an orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R, currently in development for the treatment for tenosynovial giant cell tumor (TGCT). The Director of CTCE is a critical commercial role that will be instrumental to Deciphera’s continued success in driving brand results for multiple assets, maintaining a best-in class field team and cultivating the commercial team culture.
What You’ll Do:
Training Responsibilities
Communication and Commercial Engagement Responsibilities
What You'll Bring:
Deciphera offers a comprehensive benefits package that includes but is not limited to the following:
Deciphera, a member of ONO, is a company headquartered in Waltham, Massachusetts. Our state-of-the-art research facility is located in Lawrence, Kansas and our European operations are run out of Switzerland.
EQUAL EMPLOYMENT OPPORTUNITY INFORMATION
Deciphera is committed to equal employment opportunity and values diversity. To ensure that we comply with reporting requirements and to learn more about how we can increase diversity in our candidate pool, we invite you to voluntarily provide demographic information in a confidential survey at the end of this application. Providing this information is optional. It will not be accessible or used in the hiring process, and has no effect on your opportunity for employment. This information will also be treated confidentially. Our commitment to increasing diversity in our candidate pool does not affect our commitment to equal employment opportunity, including our ongoing commitment to make all hiring and other employment decisions solely on a nondiscriminatory basis.
Passion. Commitment. Culture. At Deciphera, we are committed to improving the lives of people living with cancer. That passion for making a difference extends to the patient groups and communities in which we live and work. We recognize the value...
2 jobsSubscribe to Rise newsletter